In Transition? Bayer Exercises Option To Up Stake In JV With Zydus

Bayer is increasing its holding in its long-standing joint venture with Zydus Cadila in India by 25%, sparking off some speculation on the alliance’s future trajectory.

Steps — BAYER IS RAISING ITS HOLDING IN AN INDIAN JV

Partners Bayer and Cadila Healthcare Ltd. are tweaking the holding structure of Bayer Zydus Pharma Private Limited, their long-running 50:50 sales and marketing joint venture for pharmaceutical products in India.

Cadila Healthcare, the flagship company of the Zydus Cadila group, said that it was divesting 12,500,001 equity shares “at a value determined in terms of their joint venture agreement” to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

29 May 2025

• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

All Over For iTeos But Applause For Plan To Return Cash Fast

29 May 2025

• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

29 May 2025

• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

29 May 2025

• By Jung Won Shin

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.